Diagnostic testing involves tests and procedures to confirm the presence of disease and identify the correct tumor type, location, extent and stage. The cancer diagnostics include sophisticated diagnostic technology to evaluate tumors and develop a personalized treatment plan. Some types of cancer, such as lymphomas, can be hard to classify, even for an expert. The method for the treatment and diagnosis of the disease depends on the patient and the severity of the cancer. The most common diagnostic methods include endoscopy, biopsy, diagnostic imaging and blood tests.
The cancer diagnostics market of is expected to grow with a significant rate in the forecast years, owing to driving factors such as, increasing prevalence of cancer, technological improvements, public-private partnerships to improve the infrastructure of diagnostic imaging centers and FDA support for biomarker development. The companion diagnostics, personalized medicine are likely to offer more opportunities in the cancer diagnostics market.
The “Global Cancer Diagnostics Market Analysis To 2025” is a specialized and in-depth study of the medical device industry with a focus on the global market trend. The report aims to provide an overview of global cancer diagnostics market with detailed market segmentation by technology, application and geography. The global cancer diagnostics market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading market players and offers key trends and opportunities in the cancer diagnostics market.
The global cancer diagnostics market is segmented on the basis of technology and application. The technology segment includes fluorescent in situ hybridization (FISH), comparative genomic hybridization (CGH), immunohistochemical (IHC) and others. The application segment is classified as breast cancer, lung cancer, melanoma, colorectal cancer and other cancers.
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global cancer diagnostics market based on technology, application and geography. It also provides market size and forecast till 2025 for overall cancer diagnostics market with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 13 counties globally along with current trend and opportunities prevailing in the region.
North America is expected to contribute to the largest share in the cancer diagnostics market in the coming years, owing to factors such as, various market players operate in this region. The European region is expected to hold the second largest market for the cancer diagnostics. Asia Pacific is anticipated to be the fastest growing market as the due to the growing number of the cancer cases in the countries.
The report analyzes factors affecting market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the market in these regions.
The report also includes the profiles of key cancer diagnostics market manufacturing companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, products and services offered, financial information of last 3 years, key development in past five years. Some of the key players influencing the market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., Illumina, Inc., Merck KGaA, GenScript, Cell Signaling Technology, Inc., PerkinElmer Inc., Cancer Diagnostics, Inc. and MultiplexDx International.
TABLE OF CONTENTS
LIST OF TABLES
LIST OF FIGURES
The List of Companies
1. F. Hoffmann-La Roche AG
2. Thermo Fisher Scientific, Inc.
3. Agilent Technologies, Inc.
4. Illumina, Inc.
5. Merck KGaA
7. Cell Signaling Technology, Inc.
8. PerkinElmer Inc.
9. Cancer Diagnostics, Inc.
10. MultiplexDx International